Maze Therapeutics, Inc. (MAZE) Stock Analysis
Healthcare · Biotechnology
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule... Read more
TrendMatrix rates Maze Therapeutics, Inc. (MAZE) as Sell with moderate confidence. The stock trades at $31.70 with +59.8% upside to the $50.77 price target. Overall score: 5.0/10 across 10 analysis dimensions. Reward/risk ratio: 6.6:1.
Passes 3/4 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags). Fails on weak momentum. Suitability: aggressive.
Investment Thesis
Fundamentals
Frequently Asked Questions
TrendMatrix rates Maze Therapeutics, Inc. (MAZE) as Sell with moderate confidence. Score 5.0/10.
Take-profit target: $50.77 (+59.8% upside). Reward/risk ratio: 6.6:1. Stop-loss: $28.88.
Quality below floor (1.7 < 4.0).
Maze Therapeutics, Inc. trades at a P/E of N/A (forward -15.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
12 analysts cover MAZE with a consensus score of 4.3/5. Average price target: $60.
What does Maze Therapeutics, Inc. do?Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for...
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. The company also offers MZE001, a clinical program for the treatment of Pompe disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.